Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma.
Supraventricular tachycardia (SVT), being atrioventricular re-entry the underlying mechanism, is the most frequent tachyarrhythmia requiring a medical treatment in infants with no cardiac disease. The acute treatment of a single episode of SVT has generally an excellent prognosis. An antiarrhythmic prophylaxis of SVT recurrences is usually recommended during the first year of life. Although many efficient drugs are available for the SVT treatment, a careful risk-benefit analysis of each single case should suggest the correct drug choice.
Tavera
Maria Cristina
MC
Division of Paediatric Cardiology, G. Brotzu Hospital, Cagliari, Italy.
Bassareo
Pier Paolo
PP
Neroni
Paola
P
Follese
Chiara
C
Manca
Donatella
D
Montis
Sabrina
S
Tumbarello
Roberto
R
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods; D002755:Choice Behavior / Q000502:physiology; D003657:Decision Making / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy* / Q000517:prevention & control; D055502:Secondary Prevention; D013617:Tachycardia, Supraventricular / Q000188:drug therapy* / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents